United Therapeutics
UTHR
473 hedge funds and large institutions have $9.94B invested in United Therapeutics in 2023 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 192 increasing their positions, 160 reducing their positions, and 74 closing their positions.
30% more call options, than puts
Call options by funds: $22.4M | Put options by funds: $17.2M
20% more repeat investments, than reductions
Existing positions increased: 192 | Existing positions reduced: 160
2.49% less ownership
Funds ownership: 98.65% → 96.16% (-2.5%)
6% less funds holding
Funds holding: 505 → 473 (-32)
15% less capital inflows, than outflows
Capital inflows: $810M | Capital outflows: $950M
18% less funds holding in top 10
Funds holding in top 10: 17 → 14 (-3)
41% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$201M |
| 2 |
OrbiMed
New York
|
+$89M |
| 3 |
BlackRock
New York
|
+$76.4M |
| 4 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$44.3M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$30.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$107M |
| 2 |
Farallon Capital Management
San Francisco,
California
|
-$104M |
| 3 |
Polar Capital Holdings
London,
United Kingdom
|
-$72.6M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$44.4M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$39.3M |
UTHR Hedge Fund Activity: Q2 2023 in Review
473 of the 6,387 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2023, worth a combined $9.94B — down 1.9% from $10.1B a quarter earlier.
Sellers outnumbered buyers: 74 funds closed out of UTHR and 44 opened new positions — a net loss of 30 holders — while 160 trimmed existing stakes and 192 added.
The largest buyer was Wellington Management Group, adding an estimated $201M. The largest seller was Envestnet Asset Management, cutting an estimated $107M.
- 473 institutional investors held United Therapeutics (UTHR) as of Q2 2023, down from 505 in Q1 2023.
- Funds reported $9.94B of United Therapeutics stock for Q2 2023, down 1.9% quarter-over-quarter.
- 44 funds opened new United Therapeutics positions in Q2 2023 and 74 closed out, a net change of -30 holders.
- The largest United Therapeutics buyer in Q2 2023 was Wellington Management Group, an estimated $201M added.
- The largest United Therapeutics seller in Q2 2023 was Envestnet Asset Management, an estimated $107M sold.
Based on aggregated 13F filings for Q2 2023.